AC
MRSN

Athanor Capital’s Mersana Therapeutics MRSN Stock Holding History

Athanor Capital’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-602
Closed -$401K – 966
2020
Q4 		$401K Buy
+602
New +$335K 0.01% 514
2020
Q3 		– Sell
-973
Closed -$569K – 622
2020
Q2 		$569K Buy
+973
New +$332K 0.03% 282

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Athanor Capital's MRSN Position: Q1 2021 in Review

Athanor Capital sold out of Mersana Therapeutics (MRSN) in Q1 2021, closing a stake of 602 shares — an estimated $401K sold.

Athanor Capital first reported a position in MRSN in Q2 2020 and held it in 2 quarters. The position peaked at $569K in Q2 2020. 132 funds tracked by Wall St. Rank hold MRSN as of Q1 2021.

  • Athanor Capital reported no remaining Mersana Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 602 Mersana Therapeutics shares in Q1 2021, an estimated $401K.
  • Athanor Capital first reported a position in Mersana Therapeutics in Q2 2020 and held it in 2 quarters.
  • Athanor Capital's Mersana Therapeutics position peaked at $569K in Q2 2020.
  • 132 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.